German drug maker Merck KGaA will collaborate with Japanese drug maker Ono Pharmaceutical to develop oral therapies for cancer and multiple sclerosis, Merck KGaA said.
A drug under investigation by Sanofi for multiple sclerosis improved several measures of disease activity in patients, according to results of a late-stage clinical trial.
The Food and Drug Administration has accepted a regulatory approval application from Merck and Ariad Pharmaceuticals for a new drug to treat soft-tissue and bone cancers, the drug makers said Wednesday.
Growing numbers of Americans with asthma and chronic obstructive pulmonary disease are driving innovation among drug makers, according to a new report by Frost & Sullivan.
The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO's drugs by the end of the decade.
Supermarket pharmacies could see a slight rise in gross profits next year as branded drugs lose patent protection and go generic, according to a new report by Moody's Investors Service.
AmerisourceBergen on Tuesday purchased TheraCom, a subsidiary of CVS Caremark that provides a wide range of support to pharmaceutical and biotechnology drug manufacturers, including consulting and reimbursement services, for $250 million.
It’s hard to disagree that generic drug companies have had a good run for the last several years. Branded drug companies developed a large number of drugs that proved highly effective at treating widespread medical conditions and became blockbusters, garnering billions of dollars in sales in the United States alone.
As the clock winds down on the patent exclusivity of the industry’s biggest blockbuster drug in November, speculation continues to grow that Pfizer will look to flip the switch on an OTC version of Lipitor (atorvastatin) before generic competition whittles away at the $7 billion behemoth.
Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.
GlaxoSmithKline on Thursday announced that 25-year veteran Clark Brown, VP sales at GSK Consumer Healthcare, will be leaving the organization effective Sept. 2.